{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T18:04:57Z","timestamp":1786125897184,"version":"build-2736575974"},"reference-count":50,"publisher":"Mattioli1885","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Introduction: CDK4\/6 inhibitors have revolutionized the therapeutic management of metastatic estrogen receptor-positive (ER+), HER2-negative breast cancer (BC) by increasing treatment efficacy while maintaining a favorable safety profile. An exceedingly rare adverse event associated with these agents is the development of vitiligo-like skin depigmentation. Objectives: This study aimed to characterize a case of ribociclib-induced vitiligo and investigate its underlying pathogenic mechanisms, with particular focus on vitiligo onset. We report the case of a 60-year-old postmenopausal female with metastatic, hormone-sensitive BC who experienced a durable partial remission during treatment with ribociclib in combination with aromatase inhibitors. During therapy, the patient developed hypopigmented lesions on her upper limbs 34 months after initiation of ribociclib, preceded by pruritus and erythema. Methods: Reflectance confocal microscopy (RCM) optical coherence tomography (OCT), and histopathological examination were used. Result: RCM and OCT proved valuable for real-time assessment and monitoring of skin changes, thereby informing clinical decisions regarding the management of skin toxicity. The presence of an inflammatory infiltrate, comprising lymphocytes and hyper-reflective inflammatory cells, suggests that inhibition of the CDK4\/6 pathway may enhance antitumor activity beyond cell cycle arrest by modulating the immune response and promoting immune-mediated tumor control. Conclusions: The observed alterations in melanocyte regression could represent evidence of systemic immune activation and autoimmunity influencing melanocyte viability. These mechanisms may have significant implications for improving patient prognosis.<\/jats:p>","DOI":"10.5826\/dpc.1603a6849","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:08:12Z","timestamp":1785510492000},"page":"6849","source":"Crossref","is-referenced-by-count":0,"title":["Ribociclib-Induced Vitiligo: A Case Report with Histological, Dermatoscopic, Confocal Microscopy, and LC-OCT Findings Along with a Narrative Literature Review"],"prefix":"10.5826","volume":"16","author":[{"given":"Silvia","family":"Mezi","sequence":"first","affiliation":[{"name":"Department of Radiological, Oncological and Pathological Science, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Persechino","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ascione","sequence":"additional","affiliation":[{"name":"epartment of Experimental Medicine, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Chiavassa","sequence":"additional","affiliation":[{"name":"Department of Radiological, Oncological and Pathological Science, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"Artemi","sequence":"additional","affiliation":[{"name":"Department of Radiological, Oncological and Pathological Science, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Capasso","sequence":"additional","affiliation":[{"name":"Department of Radiological, Oncological and Pathological Science, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Amato","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Paganelli","sequence":"additional","affiliation":[{"name":"IDI-IRCCS Istituto Dermopatico dell'Immacolata, Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Pellacani","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27750","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"10.5826\/dpc.1603a6849_ref1","unstructured":"Curigliano, L Castelo-Branco, A Gennari, N Harbeck, C Criscitiello and D Trapani, ESMO Metasta-tic Breast Cancer Living Guidelines, v1.1 May 2023 Ann Oncol 2021;32(12): 1475-1495."},{"key":"10.5826\/dpc.1603a6849_ref2","unstructured":"Loibl, S. et al.: Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606 Annals of Oncology, Volume 35, Issue 2, 159 -182."},{"key":"10.5826\/dpc.1603a6849_ref3","doi-asserted-by":"crossref","unstructured":"Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im YH, Kuemmel S, El-Saghir N, Liu MC, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu YS. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a 1andomized phase 3 trial. Lancet Oncol. 2018 Jul;19(7):904-915. Doi: 10.1016\/S1470-2045(18)30292-4. Epub 2018 May 24. PMID: 29804902..","DOI":"10.1016\/S1470-2045(18)30292-4"},{"key":"10.5826\/dpc.1603a6849_ref4","doi-asserted-by":"crossref","unstructured":"Slamon DJ, Di\u00e9ras V, Rugo HS, Harbeck N, Im SA, Gelmon KA, Lipatov ON, Walshe JM, Martin M, Chavez-MacGregor M, Bananis E, Gauthier E, Lu DR, Kim S, Finn RS. Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer. J Clin Oncol. 2024 Mar 20;42(9):994-1000. Doi: 10.1200\/JCO.23.00137. Epub 2024 Jan 22. PMID: 38252901; PMCID: PMC10950136.","DOI":"10.1200\/JCO.23.00137"},{"key":"10.5826\/dpc.1603a6849_ref5","doi-asserted-by":"crossref","unstructured":"Cristofanilli M, Rugo HS, Im SA, Slamon DJ, Harbeck N, Bondarenko I, Masuda N, Colleoni M, DeMichele A, Loi S, Iwata H, O\u2019Leary B, Andr\u00e9 F, Loibl S, Bananis E, Liu Y, Huang X, Kim S, Lechuga Frean MJ, Turner NC. Overall Survival with Palbociclib and Fulvestrant in Women with HR+\/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Ran-domized Study. Clin Cancer Res. 2022 Aug 15;28(16):3433-3442. Doi: 10.1158\/1078-0432.CCR-22-0305. PMID: 35552673; PMCID: PMC9662922.","DOI":"10.1158\/1078-0432.CCR-22-0305"},{"key":"10.5826\/dpc.1603a6849_ref6","doi-asserted-by":"crossref","unstructured":"Goetz MP, Toi M, Huober J, Sohn J, Tr\u00e9dan O, Park IH, Campone M, Chen SC, Manso LM, Paluch-Shimon S, Freedman OC, O\u2019Shaughnessy J, Pivot X, Tolaney SM, Hurvitz SA, Llombart-Cussac A, Andr\u00e9 V, Saha A, van Hal G, Shahir A, Iwata H, Johnston SRD. Abemaciclib plus a non-steroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final over-all survival results of MONARCH 3. Ann Oncol. 2024 Aug;35(8):718-727. Doi: 10.1016\/j.annonc.2024.04.013. Epub 2024 May 8. PMID: 38729566.","DOI":"10.1016\/j.annonc.2024.04.013"},{"key":"10.5826\/dpc.1603a6849_ref7","doi-asserted-by":"crossref","unstructured":"Wekking D, Leoni VP, Lambertini M, Dess\u00ec M, Pretta A, Cadoni A, Atzori L, Scartozzi M, Solinas C. CDK4\/6 inhibition in hormone receptor-positive\/HER2-negative breast cancer: Biological and clini-cal aspects. Cytokine Growth Factor Rev. 2024 Feb;75:57-64. doi: 10.1016\/j.cytogfr.2023.10.001. Epub 2023 Oct 5. PMID: 37838584.","DOI":"10.1016\/j.cytogfr.2023.10.001"},{"key":"10.5826\/dpc.1603a6849_ref8","doi-asserted-by":"crossref","unstructured":"Lloyd MR, Jhaveri K, Kalinsky K, Bardia A, Wander SA. Precision therapeutics and emerging stra-tegies for HR-positive metastatic breast cancer. Nat Rev Clin Oncol. 2024 Oct;21(10):743-761. doi: 10.1038\/s41571-024-00935-6. Epub 2024 Aug 23. PMID: 39179659.","DOI":"10.1038\/s41571-024-00935-6"},{"key":"10.5826\/dpc.1603a6849_ref9","doi-asserted-by":"crossref","unstructured":"Uzhachenko, Roman V. et al. Metabolic modulation by CDK4\/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors. Cell Reports, Volume 35, Issue 1, 108944","DOI":"10.1016\/j.celrep.2021.108944"},{"key":"10.5826\/dpc.1603a6849_ref10","doi-asserted-by":"crossref","unstructured":"Zhang S, Xu Q, Sun W, Zhou J, Zhou J. Immunomodulatory effects of CDK4\/6 inhibitors. Biochim Biophys Acta Rev Cancer. 2023 Jul;1878(4):188912. doi: 10.1016\/j.bbcan.2023.188912. Epub 2023 May 12. PMID: 37182667.","DOI":"10.1016\/j.bbcan.2023.188912"},{"key":"10.5826\/dpc.1603a6849_ref11","doi-asserted-by":"crossref","unstructured":"Spring LM, Zangardi ML, Moy B, Bardia A. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4\/6 Inhibitors in Breast Cancer: Practical Conside-rations and Recommendations. Oncologist. 2017 Sep;22(9):1039-1048. doi: 10.1634\/theoncologist.2017-0142. Epub 2017 Jul 13. PMID: 28706010; PMCID: PMC5599204.","DOI":"10.1634\/theoncologist.2017-0142"},{"key":"10.5826\/dpc.1603a6849_ref12","doi-asserted-by":"crossref","unstructured":"Raschi E, Fusaroli M, La Placa M, Ardizzoni A, Zamagni C, Poluzzi E, De Ponti F. Skin Toxicities with Cyclin-Dependent Kinase 4\/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System. Am J Clin Dermatol. 2022 Mar;23(2):247-255. doi: 10.1007\/s40257-021-00645-0. Epub 2021 Oct 26. PMID: 34699032.","DOI":"10.1007\/s40257-021-00645-0"},{"key":"10.5826\/dpc.1603a6849_ref13","doi-asserted-by":"crossref","unstructured":"Silvestri M, Cristaudo A, Morrone A, Messina C, Bennardo L, Nistic\u00f2 SP, Mariano M, Cameli N. Emerging Skin Toxicities in Patients with Breast Cancer Treated with New Cyclin- Dependent Ki-nase 4\/6 Inhibitors: A Systematic Review. Drug Saf. 2021 Jul;44(7):725-732.doi: 10.1007\/s40264-021-01071-1. Epub 2021 May 6. PMID: 33959899.","DOI":"10.1007\/s40264-021-01071-1"},{"key":"10.5826\/dpc.1603a6849_ref14","doi-asserted-by":"crossref","unstructured":"Wekking D, Lambertini M, Dess\u00ec M, Denaro N, Bardanzellu F, Garrone O, Scartozzi M, Solinas C. CDK4\/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity and safety. Semin Oncol. 2023 Dec;50(6):131-139. doi: 10.1053\/j.seminoncol.2024.01.002. Epub 2024 Jan 13. PMID: 38245458.","DOI":"10.1053\/j.seminoncol.2024.01.002"},{"key":"10.5826\/dpc.1603a6849_ref15","doi-asserted-by":"crossref","unstructured":"Sollena P, Vasiliki N, Kotteas E, Stratigos AJ, Fattore D, Orlandi A, Mannino M, Di Pumpo M, Fida M, Starace M, Apalla Z, Romano MC, Riganti J, Segura S, Martinez AF, Fabbrocini G, Sibaud V, Pe-ris K, On Behalf Of The Eadv Task Force Dermatology For Cancer Patients. Cyclin-Dependent Ki-nase 4\/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force &quot;Dermatology for Cancer Patients&quot; International Study.Cancers (Basel). 2023 Jul 18;15(14):3658. Doi:0.3390\/cancers15143658. PMID: 37509319; PMCID: PMC10377938.","DOI":"10.3390\/cancers15143658"},{"key":"10.5826\/dpc.1603a6849_ref16","doi-asserted-by":"crossref","unstructured":"Anjaneyan G, Keechilat P, Duraisamy P, Eapen M. Ribociclib-induced extensive vitiligo-like le-sions: possible pathomechanisms with clinical, dermoscopic and histological correlation. BMJ Case Rep. 2022 Apr 1;15(4):e248782. doi: 10.1136\/bcr-2022-248782. PMID: 35365472; PMCID: PMC8977742","DOI":"10.1136\/bcr-2022-248782"},{"key":"10.5826\/dpc.1603a6849_ref17","doi-asserted-by":"crossref","unstructured":"Pasqualoni M, Orlandi A, Palazzo A, Garufi G, Cannizzaro MC, Pontolillo L, Pannunzio S, Cutigni C, Sollena P, Federico F, Bria E, Tortora G. Case report: Vitiligo-like toxicity due to ribociclib during first-line treatment of metastatic breast cancer: two cases of premature interruption of therapy and exceptional response. Front Oncol. 2023 Mar 9;13:1067264. doi: 10.3389\/fonc.2023.1067264. PMID: 36969030; PMCID: PMC10034067.","DOI":"10.3389\/fonc.2023.1067264"},{"key":"10.5826\/dpc.1603a6849_ref18","doi-asserted-by":"crossref","unstructured":"Chan OB, Su JC, Yazdabadi A, Chan A. Drug induced vitiligo-like depigmentation from a CDK 4\/6 inhibitor. Asia Pac J Clin Oncol. 2022 Apr;18(2):e154-e156. doi: 10.1111\/ajco.13585. Epub 2021 Jun 28. PMID: 34180575.","DOI":"10.1111\/ajco.13585"},{"key":"10.5826\/dpc.1603a6849_ref19","doi-asserted-by":"crossref","unstructured":"Sollena P, Nikolaou V, Soupos N, Kotteas E, Voudouri D, Stratigos AJ, Fattore D, Annunziata MC, Orlandi A, Di Nardo L, Apalla Z, Deilhes F, Romano MC, Fabbrocini G, Sibaud V, Peris K; Euro-pean Network for Cutaneous ADverse event of Oncologic drugs (ENCADO) group. Vitiligo-like le-sions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors. Breast Cancer Res Treat. 2021 Jan;185(1):247-253. doi: 10.1007\/s10549-020-05914-w. Epub 2020 Sep 10. PMID: 32914354.","DOI":"10.1007\/s10549-020-05914-w"},{"key":"10.5826\/dpc.1603a6849_ref20","doi-asserted-by":"crossref","unstructured":"T\u00fcrkel A, Kara\u00e7in C, \u00d6ner \u0130, \u015eeyran E, \u00d6ks\u00fczo\u011flu B. Vitiligo-like lesions associated with ribociclib in a woman with metastatic breast cancer. J Oncol Pharm Pract. 2023 Feb 9:10781552231156521. doi: 10.1177\/10781552231156521. Epub ahead of print. PMID: 36760158.","DOI":"10.1177\/10781552231156521"},{"key":"10.5826\/dpc.1603a6849_ref21","doi-asserted-by":"crossref","unstructured":"Bang AS, Fay CJ, LeBoeuf NR, Etaee F, Leventhal JS, Sibaud V, Arbesman J, Wang JY, Kwong BY. Multi-center retrospective review of vitiligo-like lesions in breast cancer patients treated with cy-clin- dependent kinase 4 and 6 inhibitors. Breast Cancer Res Treat. 2024 Apr;204(3):643-647. Doi: 10.1007\/s10549-023-07217-2. Epub 2024 Jan 15. PMID: 38224427.","DOI":"10.1007\/s10549-023-07217-2"},{"key":"10.5826\/dpc.1603a6849_ref22","doi-asserted-by":"crossref","unstructured":"Gao S, Wei G, Hao Y. Vitiligo-like lesions induced by cyclin-dependent kinase 4\/6 inhibitorPalbo-ciclib: a case report and literature review. Pathol Oncol Res. 2023 Jul 6;29:1611115.doi: 10.3389\/pore.2023.1611115. PMID: 37483648; PMCID: PMC10358287.","DOI":"10.3389\/pore.2023.1611115"},{"key":"10.5826\/dpc.1603a6849_ref23","doi-asserted-by":"crossref","unstructured":"Spritz RA, Andersen GH. Genetics of Vitiligo. Dermatol Clin. 2017 Apr;35(2):245-255. doi: 10.1016\/j.det.2016.11.013. PMID: 28317533; PMCID: PMC5362127.","DOI":"10.1016\/j.det.2016.11.013"},{"key":"10.5826\/dpc.1603a6849_ref24","doi-asserted-by":"crossref","unstructured":"Pervaiz N, Kaur H, Parsad D, Kumar R. Immune-modulatory effects of lenalidomide inhibited the progression of lesions in a vitiligo mouse model. Pigment Cell Melanoma Res. 2021 Sep;34(5):918-927. doi: 10.1111\/pcmr.12962. Epub 2021 Feb 9. PMID: 33522688.","DOI":"10.1111\/pcmr.12962"},{"key":"10.5826\/dpc.1603a6849_ref25","doi-asserted-by":"crossref","unstructured":"Frisoli ML, Harris JE. Vitiligo: Mechanistic insights lead to novel treatments. J Allergy Clin Immu-nol. 2017 Sep;140(3):654-662. doi: 10.1016\/j.jaci.2017.07.011. Epub 2017 Aug 1. PMID: 28778794.","DOI":"10.1016\/j.jaci.2017.07.011"},{"key":"10.5826\/dpc.1603a6849_ref26","doi-asserted-by":"crossref","unstructured":"Abdelsalam M, Allam SH, Zohdy M, Magdy H, Mostafa M.J Genet Eng Biotechnol. 2021 Sep 1;19(1):132. doi: 10.1186\/s43141-021-00218-y. TLR4 gene polymorphisms in Egyptian vitiligo patients: insights into emerging association with clinical activity, family history, and response to therapy. J Genet Eng Biotechnol. 2021 Sep 1;19(1):132. doi: 10.1186\/s43141-021-00218-y.","DOI":"10.1186\/s43141-021-00218-y"},{"key":"10.5826\/dpc.1603a6849_ref27","unstructured":"Abyaneh, M. A., Falto-Aizpurua, L., Pasche, F., & Nouri, K. (2014). Narrowband ultraviolet B phototherapy in combination with other therapies for vitiligo: mechanisms and efficacies. Journal of the European Academy of Dermatology and Venereology, 29(2), 221-228."},{"key":"10.5826\/dpc.1603a6849_ref28","doi-asserted-by":"crossref","unstructured":"Yousefian F, Yadlapati S, Browning JC. The use of Janus kinase inhibitors and narrowband ultra-violet B combination therapy in non-segmental vitiligo. J Cosmet Dermatol. 2023 Mar;22(3):1105-1107. doi: 10.1111\/jocd.15537. Epub 2022 Nov 28. PMID: 36440703.","DOI":"10.1111\/jocd.15537"},{"key":"10.5826\/dpc.1603a6849_ref29","doi-asserted-by":"crossref","unstructured":"Boone MA, Marneffe A, Suppa M, Miyamoto M, Alarcon I, Hofmann-Wellenhof R, Malvehy J, Pel-lacani G, Del Marmol V. High-definition optical coherence tomography algorithm for the discrimi-nation of actinic keratosis from normal skin and from squamous cell carcinoma. J Eur Acad Der-matol Venereol. 2015 Aug;29(8):1606-15. doi: 10.1111\/jdv.12954. Epub 2015 Feb 5. PMID: 25656269.","DOI":"10.1111\/jdv.12954"},{"key":"10.5826\/dpc.1603a6849_ref30","doi-asserted-by":"crossref","unstructured":"Boone MA,Norrenberg, S., Jemec, G. B., & Del Marmol, V. (2012). Imaging of basal cell carcinoma by high-definition optical coherence tomography: histomorphological correlation. A pilot study. The British Journal of Dermatology, 167(4), 856-864. doi: 10.1111\/j.1365-2133.2012.11194.x","DOI":"10.1111\/j.1365-2133.2012.11194.x"},{"key":"10.5826\/dpc.1603a6849_ref31","doi-asserted-by":"crossref","unstructured":"Boone MA, Suppa M, Dhaenens F, Miyamoto M, Marneffe A, Jemec GB, Del Marmol V, Nebosis R. In vivo assessment of optical properties of melanocytic skin lesions and differentiation of mela-noma from non-malignant lesions by high-definition optical coherence tomography. Arch Dermatol Res. 2016 Jan;308(1):7-20. doi: 10.1007\/s00403-015-1608-5","DOI":"10.1007\/s00403-015-1608-5"},{"key":"10.5826\/dpc.1603a6849_ref32","doi-asserted-by":"crossref","unstructured":"Kaur A, Barman KD, Sahoo B, Choudhary P. A comparative interventional study of narrowband ul-traviolet B alone and narrowband ultraviolet B in combination with microneedling in patients with stable vitiligo. Photodermatol Photoimmunol Photomed. 2023 Jul;39(4):357-363. doi: 10.1111\/phpp.12847. Epub 2022 Dec 7. PMID: 36419200.","DOI":"10.1111\/phpp.12847"},{"key":"10.5826\/dpc.1603a6849_ref33","doi-asserted-by":"crossref","unstructured":"Kato H, Furuhashi T, Ito E, Kaneko N, Nakamura M, Watanabe S, Shintani Y, Maeda A, Yamaguchi Y, Morita A. Efficacy of 1-mm minigrafts in treating vitiligo depends on patient age, disease site and vitiligo subtype. J Dermatol. 2011 Dec;38(12):1140-5. doi: 10.1111\/j.1346-8138.2010.01184.x. Epub 2011 Sep 27. PMID: 21951328.","DOI":"10.1111\/j.1346-8138.2010.01184.x"},{"key":"10.5826\/dpc.1603a6849_ref34","doi-asserted-by":"crossref","unstructured":"Seneschal J, Speeckaert R, Ta\u00efeb A, Wolkerstorfer A, Passeron T, Pandya AG, Lim HW, Ezzedine K, Zhou Y, Xiang F, Thng S, Tanemura A, Suzuki T, Rosmarin D, Rodrigues M, Raboobee N, Pliszew-ski G, Parsad D, Oiso N, Monteiro P, Meurant JM, Maquignon N, Lui H, Le Poole C, Leone G, Lee AY, Lan E, Katayama I, Huggins R, Oh SH, Harris JE, Hamzavi IH, Gupta S, Grimes P, Goh BK, Ghia D, Esmat S, Eleftheriadou V, B\u00f6hm M, Benzekri L, Bekkenk M, Bae JM, Alomar A, Abdallah M, Picardo M, van Geel N. Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the international Vitiligo Task Force-Part 2: Specific treatment recommendations. J Eur Acad Dermatol Venereol. 2023 Nov;37(11):2185-2195. doi: 10.1111\/jdv.19450. Epub 2023 Sep 15. PMID: 37715487.","DOI":"10.1111\/jdv.19450"},{"key":"10.5826\/dpc.1603a6849_ref35","doi-asserted-by":"crossref","unstructured":"Lommerts JE, Bekkenk MW, Luiten RM. Vitiligo induced by immune checkpoint inhibitors in mel-anoma patients: an expert opinion. Expert Opin Drug Saf. 2021 Aug;20(8):883-888. doi: 10.1080\/14740338.2021.1915279. Epub 2021 Apr 27. PMID: 33896329.","DOI":"10.1080\/14740338.2021.1915279"},{"key":"10.5826\/dpc.1603a6849_ref36","doi-asserted-by":"crossref","unstructured":"De Golian E, Kwong BY, Swetter SM, Pugliese SB. Cutaneous Complications of Targeted Melano-ma Therapy. Curr Treat Options Oncol. 2016 Nov;17(11):57. doi: 10.1007\/s11864-016-0434-0. Erratum in: Curr Treat Options Oncol. 2016 Dec;17(12):63. doi: 10.1007\/s11864-016-0440-2. PMID: 27645330","DOI":"10.1007\/s11864-016-0440-2"},{"key":"10.5826\/dpc.1603a6849_ref37","doi-asserted-by":"crossref","unstructured":"Jain A. Imatinib-induced generalized vitiligo. Br J Haematol. 2022 Jun;197(5):511. doi: 10.1111\/bjh.18096. Epub 2022 Mar 14. PMID: 35285938..","DOI":"10.1111\/bjh.18096"},{"key":"10.5826\/dpc.1603a6849_ref38","doi-asserted-by":"crossref","unstructured":"Sellappan S, Grijalva R, Zhou X, Yang W, Eli MB, Mills GB, Yu D. Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line. Cancer Res. 2004 May 15;64(10):3479-85. doi: 10.1158\/0008-5472.CAN-3299-2. PMID: 15150101.","DOI":"10.1158\/0008-5472.CAN-3299-2"},{"key":"10.5826\/dpc.1603a6849_ref39","doi-asserted-by":"crossref","unstructured":"Rashighi M, Harris JE. Vitiligo Pathogenesis and Emerging Treatments. Dermatol Clin. 2017 Apr;35(2):257-265. doi: 10.1016\/j.det.2016.11.014. PMID: 28317534; PMCID: PMC5362109.","DOI":"10.1016\/j.det.2016.11.014"},{"key":"10.5826\/dpc.1603a6849_ref40","doi-asserted-by":"crossref","unstructured":"Liu Y, Deng Y, Yang C, Naranmandura H. Double-Faced Immunological Effects of CDK4\/6 Inhibi-tors on Cancer Treatment: Challenges and Perspectives. Bioengineering (Basel). 2024 Oct 29;11(11):1084. doi: 10.3390\/bioengineering11111084. PMID: 39593745; PMCID: PMC11591775","DOI":"10.3390\/bioengineering11111084"},{"key":"10.5826\/dpc.1603a6849_ref41","doi-asserted-by":"crossref","unstructured":"Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, Chhabra S, Huang W, Liu H, Aref AR, Iva-nova E, Paweletz CP, Bowden M, Zhou CW, Herter-Sprie GS, Sorrentino JA, Bisi JE, Lizotte PH, Merlino AA, Quinn MM, Bufe LE, Yang A, Zhang Y, Zhang H, Gao P, Chen T, Cavanaugh ME, Ro-de AJ, Haines E, Roberts PJ, Strum JC, Richards WG, Lorch JH, Parangi S, Gunda V, Boland GM, Bueno R, Palakurthi S, Freeman GJ, Ritz J, Haining WN, Sharpless NE, Arthanari H, Shapiro GI, Barbie DA, Gray NS, Wong KK. CDK4\/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. Cancer Discov. 2018 Feb;8(2):216-233. doi: 10.1158\/2159-8290.CD-17-0915. Epub 2017 Nov 3. PMID: 29101163; PMCID: PMC5809273.","DOI":"10.1158\/2159-8290.CD-17-0915"},{"key":"10.5826\/dpc.1603a6849_ref42","doi-asserted-by":"crossref","unstructured":"Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, Khan N, Ubellacker JM, Xie S, Metzger-Filho O, Hoog J, Ellis MJ, Ma CX, Ramm S, Krop IE, Winer EP, Roberts TM, Kim HJ, McAllister SS, Zhao JJ. CDK4\/6 inhibition triggers anti-tumour immunity. Nature. 2017 Aug 24;548(7668):471-475. Doi: 10.1038\/nature23465. Epub 2017 Aug 16. PMID: 28813415; PMCID: PMC5570667.","DOI":"10.1038\/nature23465"},{"key":"10.5826\/dpc.1603a6849_ref43","doi-asserted-by":"crossref","unstructured":"Zizzari IG, Martufi P, Battisti F, Rahimi H, Caponnetto S, Bellati F, Nuti M, Rughetti A, Napoletano C. The Macrophage Galactose-Type C-Type Lectin (MGL) Modulates Regulatory T Cell Functions. PLoS One. 2015 Jul 6;10(7):e0132617. doi: 10.1371\/journal.pone.0132617. PMID: 26147970; PMCID: PMC4493043.","DOI":"10.1371\/journal.pone.0132617"},{"key":"10.5826\/dpc.1603a6849_ref44","doi-asserted-by":"crossref","unstructured":"Scirocchi F, Scagnoli S, Botticelli A, Di Filippo A, Napoletano C, Zizzari IG, Strigari L, Tomao S, Cortesi E, Rughetti A, Marchetti P, Nuti M. Immune effects of CDK4\/6 inhibitors in patients with HR+\/HER2- metastatic breast cancer: Relief from immunosuppression is associated with clinical re-sponse. EBioMedicine. 2022 May;79:104010. doi: 10.1016\/j.ebiom.2022.104010. Epub 2022 Apr 25. PMID: 35477069; PMCID: PMC9061627.","DOI":"10.1016\/j.ebiom.2022.104010"},{"key":"10.5826\/dpc.1603a6849_ref45","doi-asserted-by":"crossref","unstructured":"Rebaudi, Federico et al. The landscape of combining immune checkpoint inhibitors with novel Therapies: Secret alliances against breast cancerCancer Treatment Reviews, Volume 130, 102831","DOI":"10.1016\/j.ctrv.2024.102831"},{"key":"10.5826\/dpc.1603a6849_ref46","doi-asserted-by":"crossref","unstructured":"Chen ST, Semenov YR, Alloo A, et al Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapyJournal for ImmunoTherapy of Cancer 2024;12:e007675. doi: 10.1136\/jitc-2023-007675","DOI":"10.1136\/jitc-2023-007675"},{"key":"10.5826\/dpc.1603a6849_ref47","doi-asserted-by":"crossref","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, Andr\u00e9 F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O'Shaughnessy J. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016 Nov 3;375(18):1738-1748. doi: 10.1056\/NEJMoa1609709. Epub 2016 Oct 7. Erratum in: N Engl J Med. 2018 Dec 27;379(26):2582. doi: 10.1056\/NEJMx180043. PMID: 27717303..","DOI":"10.1056\/NEJMoa1609709"},{"key":"10.5826\/dpc.1603a6849_ref48","doi-asserted-by":"crossref","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Mon-dal S, Su F, Miller M, Elmeliegy M, Germa C, O'Shaughnessy J. Updated results from MON-ALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018 Jul 1;29(7):1541-1547. doi: 10.1093\/annonc\/mdy155. Erratum in: Ann Oncol. 2019 Nov 1;30(11):1842. doi: 10.1093\/annonc\/mdz215. PMID: 29718092.","DOI":"10.1093\/annonc\/mdy155"},{"key":"10.5826\/dpc.1603a6849_ref49","doi-asserted-by":"crossref","unstructured":"Hernandez Navarro S, Segura Tejedor J, Bajona Roig M, Luisetto R, Fedrigo M, Castellani C, An-gelini A, Alaibac M, Bordignon M. Efficacy of a topical formulation containing MIA (Melanoma Inhibitory Activity) - Inhibitory peptides in a case of recalcitrant vitiligo in combination with UV exposure. Medicine (Baltimore). 2022 Nov 18;101(46):e31833. doi: 10.1097\/MD.0000000000031833. PMID: 36401489; PMCID: PMC9678623.","DOI":"10.1097\/MD.0000000000031833"},{"key":"10.5826\/dpc.1603a6849_ref50","doi-asserted-by":"crossref","unstructured":"Laddha NC, Dwivedi M, Mansuri MS, Gani AR, Ansarullah M, Ramachandran AV, Dalai S, Begum R. Vitiligo: interplay between oxidative stress and immune system. Exp Dermatol. 2013 Apr;22(4):245-50. doi: 10.1111\/exd.12103. Epub 2013 Feb 21. PMID: 23425123.","DOI":"10.1111\/exd.12103"}],"container-title":["Dermatology Practical &amp; Conceptual"],"original-title":[],"link":[{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/download\/6849\/3939","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/download\/6849\/3939","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:20:52Z","timestamp":1786123252000},"score":1,"resource":{"primary":{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/view\/6849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5826\/dpc.1603a6849","relation":{"has-manifestation":[{"id-type":"other","id":"1-84-6849-g3939","asserted-by":"subject"}],"is-part-of":[{"id-type":"doi","id":"10.5826\/dpc.1603a%a","asserted-by":"subject"}]},"ISSN":["2160-9381"],"issn-type":[{"value":"2160-9381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"article-number":"7"}}